Abstract. Liver cancer is a malignant tumour with high morbidity and fatality rates that is common worldwide. At present, the clinical approaches to treating primary liver cancer include partial hepatectomy, systemic or local chemotherapy, radiotherapy, radiofrequency ablative surgery and liver transplantation. However, all of these approaches have shortcomings, including poor prognosis and numerous side-effects. A large number of studies have proven that many effective ingredients in traditional Chinese medicine, particularly the flavonoid compounds extracted from plants, have achieved breakthroughs in terms of enhancing the effects and reducing the toxicity of chemotherapy and radiotherapy, preventing tumour metastasis and relapse after surgery, alleviating the clinical symptoms of advanced tumours, improving the quality of life of the patient with tumours and extending patient long-term survival. The purpose of the present study was to investigate the impact of isoquercitrin, the flavonoid from Bidens bipinnata L. extract, on the progression of liver cancer and to achieve a deeper understanding of the biological characteristics of isoquercitrin's involvement in the progression of liver cancer. In the in vitro experiments, isoquercitrin was found to strongly inhibit the proliferation of human liver cancer cells, promote the apoptosis of human liver cancer cells, and block the cell cycle in the G1 phase. Isoquercitrin activated caspase-3, -8 and -9, inhibited the expression level of ERK and p38MAPK protein phosphorylation, and promoted the phosphorylation of JNK. Additionally, isoquercitrin reduced the expression level of PKC in human liver cancer cells. In the in vivo experiments, isoquercitrin was also found to significantly inhibit the growth of transplanted tumours in nude mice. The present study confirmed that isoquercitrin could inhibit the progression of human liver cancer in vivo and in vitro, and the molecular mechanism of isoquercitrin may be closely associated with the MAPK and PKC signalling pathways.
The fruit and root of Clausena lansium are remedy for bronchitis in oriental traditional medicine. Extracts from Clausena lansium are reported to have antioxidant, anti-inflammatory, and anticancer activities. This study is designed to investigate whether the ethanol extract of Clausena lansium (Lour.) Skeels could inhibit the lipopolysaccharides (LPS)induced inflammatory in RAW 264.7 macrophages and the underlining mechanisms. Enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) are used to detect the secretion of tumor necrosis factor alpha (TNF-α) protein and expression of TNF-α mRNA, respectively. RT-PCR and Western blotting are used to determine the mRNA and protein levels of TLR4, MYD88, and TRAF6, respectively. The extract of Clausena lansium suppressed the expression and secretion of TNF-α, which is released by RAW 264.7 cells after LPS induction. Meanwhile, the expression of TLR4, MYD88, and TRAF6 are decreased by extracts from Clausena lansium. Meanwhile, NBP2-29328, an inhibitor of MYD88, synergistically enhances the inhibiting effect of extract from Clausena lansium. The results imply that ethanol extract from Clausena lansium attenuate macrophage-mediated inflammation and TLR4/ MYD88/TRAF6 pathway is its potential target.
Isoquercitrin inhibits the progression of liver cancer in vivo andin vitro via the MAPK signalling pathway guIhong huang, Bo tang, Kun tang, XIaomIn Dong, Jungang Deng, luqIn lIao, ZengZhen lIao, hua yang and songqIng he This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.